– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –– Presentation and ...
Initial data from the Phase 1 single-ascending dose trial indicates that DT-216P2 is well-tolerated, with no reported adverse events, supporting its safety profile. The dosing of the first Friedreich ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results